Journal of Cancer Research and Clinical Oncology

, Volume 123, Issue 9, pp 496–501 | Cite as

p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity

  • Peter Röhlke
  • Karin Milde-Langosch
  • Christine Weyland
  • Uwe Pichlmeier
  • Walter Jonat
  • Thomas Löning
Original Paper


p53 mutation and p53 protein overexpression are common findings in ovarian carcinomas. In order to evaluate the prognostic significance of the p53 status and its role in metastasis, we examined 104 ovarian carcinomas, among them 83 cases with follow-up data, and 40 pairs of primary tumors and metastases, by p53 immunohistochemistry and temperature-gradient gel electrophoresis. Comparison of primary tumors and their metastases revealed identical results in 88%–90% of the cases, indicating that, in most cases, mutantp53 occurs prior to metastatic spread and remains clonally conserved. With respect to all tumors, moderate/high p53 expression was significantly more prevalent in serous-papillary types, carcinomas with high grade, and high Ki67 scores, but was not associated with age, stage, or hormone receptor status. Kaplan-Meier analysis of 83 cases, followed-up for 9–96 months, demonstrated that moderate/high p53 overexpression in the group of 66 stage T3/M1 tumors was associated significantly (P=0.0028 andP=0.0105) with shorter overall and recurrence-free survival. Multivariate analysis revealed that advanced clinical stage and p53 positivity were the only independent predictive variables. No significance was seen in regard to second-look results and outcome of 50 patients receiving platinum-based chemotherapy. These observations show that p52 immunohistochemistry is an independent prognostic indicator at the given cut-off level, but does not reliably predict chemotherapy response.

Key words

Ovarian carcinoma p53 Metastasis Prognosis Ki67 



temperature-gradient gel electrophoresis


polymerase chain reaction


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G (1993) p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 24:1175–1179PubMedGoogle Scholar
  2. Eccles DM, Cranston G, Steel CM, Nakamura Y, Leonard RCF (1990) Allele losses on chromosome 17 in human epithelial ovarian cancer. Oncogene 5:1599–1601PubMedGoogle Scholar
  3. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11:1217–1228PubMedGoogle Scholar
  4. Gerdes J (1990) Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1:99–206PubMedGoogle Scholar
  5. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64–69PubMedGoogle Scholar
  6. Isola J, Kallioniemi O-P, Korte J-M, Wahlström T, Aine R, Helle M, Helin H (1990) Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J Pathol 162:295–301PubMedGoogle Scholar
  7. Kappes S, Milde-Langosch K, Kressin P, Passlack B, Dockhorn-Dworniczak B, Röhlke P, Löning T (1995) p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry, Int J Cancer 64:52–59PubMedGoogle Scholar
  8. Kiene P, Milde-Langosch K, Runkel M, Schulz K, Löning T (1992) A simple and rapid technique to process formalin-fixed, paraffin-embedded tissues for the detection of viruses by the polymerase chain reaction. Virchows Arch [A] 420:269–273Google Scholar
  9. Klemi P-J, Pylkkänen L, Kiilholma P Kurvinen K, Joensuu H (1995) P53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76:1201–1208PubMedGoogle Scholar
  10. Kupryjanczuk J, Thor AD, Beauchamp R, Merritt V Edgerton SM, Bell DA, Yandell DW (1993)p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90:4961–4965PubMedGoogle Scholar
  11. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP (1995) Mutant p53 overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75:1327–1338PubMedGoogle Scholar
  12. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Löning T (1995) Presence and persistence of HPV infection andp53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 63:639–645PubMedGoogle Scholar
  13. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly K, Parkin DE, Haites NE (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53:2128–2132PubMedGoogle Scholar
  14. Pieretti M, Powell DE, Gallion HH, Conway PS, Case EA, Turker MS (1995) Hypermethylation at a chromosome 17 “hot spot” is a common event in ovarian cancer. Hum Pathol 26:398–401PubMedGoogle Scholar
  15. Reles A, Schmider A, Press MF, Schönborn I, Friedmann W, Huber-Schumacher S, Strohmeyer T, Lichtenegger W (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 122:489–494PubMedGoogle Scholar
  16. Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pietotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study ofp53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56:689–693PubMedGoogle Scholar
  17. Selivanova G, Wiman KG (1995) P53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 66:143–180PubMedGoogle Scholar
  18. Scholz RB, Milde-Langosch K, Jung R, Schlechte H, Kabisch H, Wagener C, Löning T (1993) Rapid screening for Tp53 mutations by temperature gradient gel electrophoresis: a comparison with SSCP analysis. Hum Mol Genet 2:2155–2158PubMedGoogle Scholar
  19. Wu GS, El-Deiry WS (1996) p53 and chemosensitivity. Nat Med 2:255–256Google Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • Peter Röhlke
    • 1
  • Karin Milde-Langosch
    • 2
  • Christine Weyland
    • 1
  • Uwe Pichlmeier
    • 3
  • Walter Jonat
    • 4
  • Thomas Löning
    • 2
  1. 1.Clinics of Gynecology and ObstetricsUniversity Hospital of HamburgGermany
  2. 2.Department of Gynecological HistopathologyUniversity Clinics of Obstetrics and GynecologyHamburgGermany
  3. 3.Institute of Mathematics and Computer Science in MedicineUniversity Hospital of HamburgGermany
  4. 4.Clinics of Gynecology and ObstetricsUniversity Hospital of KielGermany

Personalised recommendations